Publications
Cholecystokinin-2 Receptor Agonist 177Lu-PP-F11N for Radionuclide Therapy of Medullary Thyroid Carcinoma – Results of the Lumed Phase 0a Study
DEBIO 1347 In Patients With GastroIntestinal Cancers Harboring An FGFR Gene Fusion: Preliminary Results
A dose-finding study of the SMAC mimetic Debio 1143 when given in combination with avelumab to patients with advanced solid…
FUZE Clinical Trial: a Phase 2 study of Debio 1347 in FGFR fusion-positive advanced solid tumors irrespectively of the tumor histology
New sample preparation method enabling PCR-based pathogen identification directly from blood to accelerate blood stream infection (BSI) diagnosis
Open-label, non-randomized, exploratory pre-operative window-of-opportunity trial to investigate the pharmacokinetics and pharmacodynamics of the smac mimetic Debio 1143 in patients…
Molecular screening of patients with FGFR alterations for a phase 1 (Ph1) study with the selective FGFR inhibitor (FGFRi) Debio…
Antitumor activity of the novel oral highly selective Wee1 inhibitor Debio 0123